Fortrea Holdings Inc

FTRE: XNAS (USA)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
$91.50SkrgvcBpwvsqbzd

Fortrea: Healthy Clinical Trial Outsourcing Demand Supports Backlog Growth; Shares Undervalued

Fortrea reported solid third-quarter results highlighted by revenue of $776 million. The company is tracking our expectations and we maintain our fair value estimate of $35.50 per share. We view shares as undervalued, currently trading about 8% below our fair value estimate. Investors reacted positively to Fortrea’s results, sending the stock up over 10%.

Sponsor Center